GeneTex’s IWGAV-inspired “Five Pillar” validation strategy is augmented by its partnership with YCharOS, an open science initiative working to improve data reproducibility through rigorous antibody validation.
Antibodies are essential tools for driving advances in biomedical science. However, poorly validated antibodies contribute to irreproducible experimental results, inefficient use of research funds, and wasted researcher time. Studies indicate that over 50% of commercially available antibodies fail to meet standardized validation criteria, underscoring the need for rigorous quality control.
GeneTex prioritizes antibody validation to ensure research reliability through stringent antibody validation. These efforts begin with our recombinant monoclonal antibody manufacturing platform that has been used to generate all of our new antibody reagents since 2020. Recombinant antibodies offer consistent performance (as well as scalability and inexhaustible supply), largely eliminating the lot-to-lot variability that can occur with both traditional polyclonal and hybridoma mouse monoclonal antibodies. GeneTex’s antibodies are then characterized with a “Five Pillar”-inspired validation framework (termed “GeneTex’s “5 + 1” Pillar Antibody Validation Process”) originally described by the International Working Group for Antibody Validation (IWGAV) (1). Through adherence to these protocols, GeneTex provides scientists with high-quality antibodies that meet top standards of specificity, sensitivity, and consistency. This meticulous approach enhances data accuracy, strengthens reproducibility, and supports scientific progress.
Complementing these manufacturing and validation workflows, GeneTex partners with the esteemed YCharOS, an open science initiative dedicated to improving research reproducibility through stringent antibody validation. YCharOS’s antibody assessment paradigm leverages target gene knockout or knockdown cell samples to evaluate a participating company’s antibodies for performance in western blot, immunoprecipitation, and immunocytochemistry. Their reports are then released and widely available. YCharOS’s recent publication in Nature Protocols highlights their strategy and this impactful collaboration, detailing their work with GeneTex and other leading reagent manufacturers (2). This publication reinforces the significance of standardized validation in ensuring antibody reliability and improving research reproducibility.
Through this partnership with YCharOS, GeneTex seeks to further enhance its high standards for antibody quality. GeneTex remains committed to innovation and excellence in antibody validation, ensuring thorough quality control and strong scientific collaborations with academic and industry scientists. Our dedication ensures that researchers can rely on GeneTex products to facilitate more robust and reliable scientific discoveries.
References:
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
